Overview
Bring Your Asset to Life
Corval is the trailblazing innovation of Sue Nemetz, a proven leader and successful entrepreneur in the life sciences industry. She is the CEO and Founder of The NemetzGroup—a thriving, strategic commercialization consultancy. With more than 35 years of corporate strategy, commercial, medical affairs, business development, and operational experience, C-suite leadership teams rely on her thought partnership and mentoring to achieve goals across all stages of drug development.
The Corval strategic planning platform serves as the foundation for early- to mid-stage biopharma commercialization efforts. It organizes all facets of commercialization and creates a comprehensive, multi-year view of what you need to do, when you need to do it, and what it will take for success.
The standard Corval subscription provides access for up to 10 users and includes a detailed 3- to 5-year plan that outlines every step of your asset’s path to market, strategic commercialization objectives that are tied to your asset’s unique development milestones organized by year and workstream, and much, much more.
Before I retire, I want to share all the answers. Corval provides the single source of truth that begins that process. —Sue Nemetz
Company News
Leveraging Technology to Accelerate Biopharma Commercialization Planning
Jul 10, 2023
Posted by Corval
